Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-12-17-Speech-3-106"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20031217.4.3-106"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
The highest degree of public health protection in the Union is a concept enshrined in the current Article 152 of the EC Treaty.
I welcome the efforts made by all institutional and private operators to improve the content of the Community code relating to medicinal products for human use. The amendments mainly concern the definition of medicinal products, generic medicinal products and organic medicinal products which, in my view, is aimed at meeting the ever-greater demands of the European citizens and the need to provide a more reliable framework for conditions for marketing medicinal products for human use.
Lastly, as I said about the other report by Mrs Grossetête, we must consider reasonable protection (in the form of a set period of time) for the rights of pharmaceutical products, specifically those that have new therapeutic indications, which provide patients with substantial clinical benefits compared to existing therapeutic indications, in order to achieve the balance suggested by the rapporteur (although not optimistic, she is at least realistic) between competitiveness, research, health system needs and the development of generic medicines.
The overall compromise that was reached with the Council under the Italian Presidency, including on the Agency covered by the Müller report, is extremely important."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples